Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism

References

• Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98–103
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, Takeshita K, Koryzna A, Donohue K, Bernstein Z, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348–3352
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Anagnostopoulos A. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. Semin Hematol 2003; 40: 8–16
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001; 85: 953–958
   PubMed Web of Science ®Google Scholar
• Hwu W J, Raizer J, Panageas K S, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2001; 2: 634–635
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K, McCarthy P, Koryzna A, Kouides P, Donohue K, et al. VAD-t (vincristine, adriamycin, dexamethasone and low-dose thalidomide) is an effective initial therapy with high response rates for patients with treatment naïve multiple myeloma (MM). Blood 2004; 104: 3463
   PubMed Web of Science ®Google Scholar
• Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74: 40–46
   PubMed Web of Science ®Google Scholar
• Hussein M A. Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist 2003; 8(Suppl 3)39–45
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35
   PubMedGoogle Scholar
• Horne M K, 3rd, Figg W D, Arlen P, Gulley J, Parker C, Lakhani N, et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 2003; 23: 315–318
   PubMed Web of Science ®Google Scholar
• Minnema M C, Breitkreutz I, Auwerda J J, van der Holt B, Cremer F W, van Marion A M, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044–2046
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721
   PubMed Web of Science ®Google Scholar
• Baz R, Marchant K, Yiannaki E, Platt L, Brand C, Tso E, et al. Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM). Blood 2004; 104: 2397
   PubMed Web of Science ®Google Scholar
• Bern M M, Lokich J J, Wallach S R, Bothe A, Jr, Benotti P N, Arkin C F, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423–428
   PubMed Web of Science ®Google Scholar
• Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101: 483–486
   PubMed Web of Science ®Google Scholar
• Dobrzanski S, Duncan S E, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharm 1983; 8: 75–77
   PubMedGoogle Scholar
• Absher R K, Moore M E, Parker M H. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512–1517
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K, McCarthy P, DiMiceli L, Yu J, Bernstein Z, et al. A Phase II study of velcade (V), doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstorm macroglobulinemia (WM). Blood 2004; 104: 2421
   Google Scholar
• Osman K, Comenzo R, Rajkumar S V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951–1952
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272–2273
   PubMed Web of Science ®Google Scholar
• Bennett C L, Schumock G T, Desai A A, Kwaan H C, Raisch D W, Newlin R, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002; 113: 603–606
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal A V, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615
   PubMed Web of Science ®Google Scholar
• Bowcock S J, Rassam S M, Ward S M, Turner J T, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7: 51–53
   PubMedGoogle Scholar
• Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Cavenagh J D, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18–26
   PubMed Web of Science ®Google Scholar
• Oakervee H, Brownell A, Cervi P, Grant I, Rahemtulla A, Child A, et al. Study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: a UK Myeloma Forum Pilot Study. Br J Haematol 2002; 117: 65
   Google Scholar
• Zervas K, Dimopoulos M A, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134–138
   PubMed Web of Science ®Google Scholar